Tesamorelin
Also known as Egrifta · TH9507
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg · 20 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Tesamorelin (TSM10) · Not in current stock
$65 / vial
2mg x 10 vials
Tesamorelin (TSM2) · Not in current stock
$35 / vial
20mg x 10 vials
Tesamorelin (TSM20) · Not in current stock
$120 / vial
5mg x 10 vials
Tesamorelin (TSM5) · Not in current stock
$45 / vial
Prices per vial · Research use only · Not medical advice.
FDA-approved GHRH analog for reducing excess abdominal fat in HIV-associated lipodystrophy; also discussed for visceral fat in biohacking circles.
How to picture it
Tesamorelin is a stabilized GHRH analog — still a formal "release GH" request to the pituitary — with clinical data on reducing deep visceral abdominal fat in a defined approved population. Picture a pituitary-level GH instruction whose research story reaches beyond hormone numbers into body-composition biology: GH/IGF-1 tone linked to visceral adipose pathways. Same axis door as other GHRH analogs, with a more specific visceral-fat research chapter.
Research focus & benefits
- Visceral adipose reduction research (HIV lipodystrophy literature)
- GH and IGF-1 elevation studies
- Metabolic marker and body-composition interest
- FDA-approved product exists for a defined indication
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Tesamorelin is a stabilized GHRH analog approved as Egrifta for reduction of excess visceral adipose tissue in specific HIV patient populations. Because of its effect on visceral fat and IGF-1, it is frequently discussed off-label in performance and longevity communities, though off-label use carries medical and legal considerations.
Mechanism
GHRH receptor agonist increasing endogenous GH and IGF-1, which can reduce visceral adipose tissue in indicated patients.
Research uses
- HIV-associated lipodystrophy (approved indication)
- Visceral adiposity research
- Cognitive and NAFLD exploratory research
Research dosing notes
Prescription product uses daily subcutaneous dosing per label for indicated patients. Off-label self-experimentation is not advised.
Half-life / kinetics
~26–38 minutes (but clinical effects via GH/IGF-1 axis)
Common research routes
Reported considerations
- Arthralgia
- Peripheral edema
- Injection-site reactions
- Elevated IGF-1
- Glucose intolerance risk
Contraindications / cautions
- Active malignancy
- Disruption of the hypothalamic-pituitary axis
- Pregnancy
- Known hypersensitivity
Common research stacks
- Lifestyle deficit
- Resistance training
- Sometimes CJC/IPA discussions (clinic-dependent)
Legal / access note
FDA-approved for a specific HIV lipodystrophy indication. Off-label and research-market versions should not be confused with the approved product.